Pan-cancer analysis of MZB1 expression and its association with immune infiltration and clinical prognosis.
10.12122/j.issn.1673-4254.2025.09.20
- Author:
Yu ZHANG
1
;
Haitao LI
1
;
Yuqing PAN
2
;
Jiexian CAO
2
;
Li ZHAI
1
;
Xi ZHANG
1
Author Information
1. Department of Clinical Laboratory, Cancer Hospital of Yunnan Province, Third Affiliated Hospital of Kunming Medical University, Kunming 650118, China.
2. Clinical Laboratory, First Affiliated Hospital of Kunming Medical University, Yunnan Key Laboratory of Laboratory Medicine, Yunnan Provincal Clinical Research Center for Laboratory Medicine, Kunming 650032, China.
- Publication Type:Journal Article
- Keywords:
immune infiltration;
marginal zone B and B1-cell-specific protein;
pan-cancer analysis;
prognosis;
therapeutic target
- MeSH:
Humans;
Prognosis;
Tumor Microenvironment;
Neoplasms/pathology*;
Cell Line, Tumor;
Mutation;
Kidney Neoplasms;
Microsatellite Instability;
Cell Proliferation;
Carcinoma, Renal Cell
- From:
Journal of Southern Medical University
2025;45(9):2006-2018
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVES:To investigate the expression levels of marginal zone B and B1-cell-specific protein (MZB1) in pan-cancer and its association with patient prognosis and tumor microenvironment (TME).
METHODS:MZB1 expression data, clinicopathological parameters, and survival data from 33 cancer types were extracted from the UCSC database for analyzing the correlations of MZB1 with clinical stage, patient prognosis, immunomodulatory genes, immune checkpoint genes, tumor stemness, immune cell infiltration, tumor mutational burden (TMB), and microsatellite instability (MSI). MZB1 gene mutations in pan-cancer were assessed using cBioPortal online database, and the value of MZB1 for cancer diagnosis was evaluated using ROC curve analysis. MZB1 expression levels in myeloid leukemia and renal carcinoma cells were detected using RT-qPCR and Western blotting, and the effect of MZB1 knockdown on cell proliferation was examined using EdU assay.
RESULTS:MZB1 was significantly overexpressed in 20 cancer types, including kidney renal clear cell carcinoma (KIRC), breast invasive carcinoma, and acute myeloid leukemia. Its expression was associated with TNM stage, clinical stage, overall survival, and progression-free survival in multiple cancers. In most tumors, MZB1 expression was correlated significantly with immunomodulatory genes, immune checkpoint genes, tumor stemness, immune cell infiltration, TMB, and microsatellite instability. Gene amplification was the predominant mutation type of MZB1 in pan-cancer, and MZB1 showed high diagnostic value for skin cutaneous melanoma, KIRC, and head and neck squamous cell carcinoma. MZB1 was highly expressed in different myeloid leukemia cell lines and renal carcinoma cell lines, and MZB1 knockdown significantly suppressed the proliferation of HL60 and 769-P cells.
CONCLUSIONS:MZB1 is highly expressed in a variety of tumors, and its aberrant expression affects the occurrence and prognosis of many tumors, suggesting its potential as a novel tumor biomarker and immunomodulatory target.
